FTC Hearing On IP Policy: Patent Eligibility Requirements Are Top Industry Concern
Supreme Court decisions on subject matter patentability have discouraged investments, panelists tell FTC; BIO says biotech companies may look outside patent system.
You may also be interested in...
The Initiative for Medicines, Access & Knowledge has responded to criticisms leveled by North Carolina senator Thom Tillis at a report it published in 2018. The report accuses pharmaceutical firms of using patent thickets to suppress generic and biosimilar competition in the US market.
Senator Tillis requests the two agencies conduct an independent analysis of I-MAK data and the ‘false narrative’ that patents are to blame for high drug prices.
BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.